Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review
Authors
Keywords
-
Journal
GENETICS IN MEDICINE
Volume 19, Issue 11, Pages 1187-1201
Publisher
Springer Nature
Online
2017-06-22
DOI
10.1038/gim.2017.30
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs and engagement approaches in health-systems research?
- (2015) Beth K. Potter et al. GENETICS IN MEDICINE
- A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II
- (2015) Joseph Muenzer et al. GENETICS IN MEDICINE
- Activities of daily living in patients with Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation
- (2015) Julian Tanjuakio et al. MOLECULAR GENETICS AND METABOLISM
- Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6years with Hunter syndrome
- (2015) Young Bae Sohn et al. MOLECULAR GENETICS AND METABOLISM
- Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
- (2015) Arian Pano et al. Orphanet Journal of Rare Diseases
- Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study
- (2015) Nathalie Guffon et al. Orphanet Journal of Rare Diseases
- Evaluating meta-ethnography: systematic analysis and synthesis of qualitative research
- (2014) R Campbell et al. HEALTH TECHNOLOGY ASSESSMENT
- The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
- (2014) K Wyatt et al. HEALTH TECHNOLOGY ASSESSMENT
- Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series
- (2014) Christina Lampe et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
- (2014) Sung Yoon Cho et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis
- (2014) Thomas Hundsberger et al. JOURNAL OF NEUROLOGY
- Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
- (2014) Rosella Tomanin et al. Orphanet Journal of Rare Diseases
- The Effect of Recombinant Human Iduronate-2-Sulfatase (Idursulfase) on Growth in Young Patients with Mucopolysaccharidosis Type II
- (2014) Zbigniew Żuber et al. PLoS One
- IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome
- (2013) J. Kim et al. ALLERGY
- A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy
- (2013) Roberto Giugliani et al. GENETICS IN MEDICINE
- The effect of idursulfase on growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS)
- (2013) Simon A. Jones et al. MOLECULAR GENETICS AND METABOLISM
- The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase
- (2013) A.J. Barbier et al. MOLECULAR GENETICS AND METABOLISM
- Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: Comparison in two siblings
- (2013) Go Tajima et al. MOLECULAR GENETICS AND METABOLISM
- Effect of rapid cessation of enzyme replacement therapy: A report of 5 more cases
- (2013) Agnieszka Jurecka et al. MOLECULAR GENETICS AND METABOLISM
- Early initiation of enzyme replacement therapy for the mucopolysaccharidoses
- (2013) Joseph Muenzer MOLECULAR GENETICS AND METABOLISM
- Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
- (2013) Young Bae Sohn et al. Orphanet Journal of Rare Diseases
- Effect of rapid cessation of enzyme replacement therapy: A report of 5 cases and a review of the literature
- (2012) Agnieszka Jurecka et al. MOLECULAR GENETICS AND METABOLISM
- Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan
- (2012) Akemi Tanaka et al. MOLECULAR GENETICS AND METABOLISM
- Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up
- (2011) A Tylki- Szymanska et al. ACTA PAEDIATRICA
- Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points
- (2011) Emma Glamuzina et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: A perspective from the Hunter Outcome Survey (HOS)
- (2011) Barbara K. Burton et al. MOLECULAR GENETICS AND METABOLISM
- Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease
- (2011) Maurizio Scarpa et al. Orphanet Journal of Rare Diseases
- Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome
- (2010) Joseph Muenzer et al. GENETICS IN MEDICINE
- GRADE guidelines: 2. Framing the question and deciding on important outcomes
- (2010) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II
- (2010) G. Schulze-Frenking et al. JOURNAL OF INHERITED METABOLIC DISEASE
- Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II — data from the Hunter Outcome Survey
- (2010) Barbara K. Burton et al. MOLECULAR GENETICS AND METABOLISM
- Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders
- (2010) Jaap J. Boelens et al. PEDIATRIC CLINICS OF NORTH AMERICA
- Incidence of the mucopolysaccharidoses in Taiwan, 1984-2004
- (2009) Hsiang-Yu Lin et al. AMERICAN JOURNAL OF MEDICAL GENETICS PART A
- Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions
- (2009) Vinod K. Prasad et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bone Marrow Transplantation in Children with Hunter Syndrome: Outcome after 7 to 17 Years
- (2009) Nathalie Guffon et al. JOURNAL OF PEDIATRICS
- Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses
- (2009) Barbara K. Burton et al. MOLECULAR GENETICS AND METABOLISM
- Japan Elaprase® Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)
- (2009) Torayuki Okuyama et al. MOLECULAR GENETICS AND METABOLISM
- Home treatment with Elaprase® and Naglazyme® is safe in patients with mucopolysaccharidoses types II and VI, respectively
- (2008) S. Bagewadi et al. JOURNAL OF INHERITED METABOLIC DISEASE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started